Carter-Wallace
This article was originally published in The Tan Sheet
Executive Summary
Rumors continue to swirl as Bristol, Tenn.-based King Pharmaceuticals denies interest in purchasing Carter-Wallace's pharmaceuticals operations, despite a press report citing King as a possible suitor for C-W's Rx business. A buzz has surrounded C-W for months based on speculation the company plans to split its Rx and consumer products divisions and sell them to separate buyers (1"The Tan Sheet" Dec. 11, 2000, In Brief)
You may also be interested in...
Carter-Wallace
President/COO Ralph Levine promoted to chairman/CEO effective Jan. 1, firm says Dec. 5. Exec VP/CFO Paul Veteri will assume the president/COO post, and Peter Griffin retains VP/controller titles while assuming CFO post. Retiring Chair Henry Hoyt to remain as chairman emeritus. Carter-Wallace reportedly is seeking to sell off its pharmaceuticals and consumer products operations to separate buyers
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands